Tarsus Pharmaceuticals, Inc. $TARS Shares Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 7.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,525 shares of the company’s stock after purchasing an additional 5,345 shares during the quarter. Lisanti Capital Growth LLC owned 0.18% of Tarsus Pharmaceuticals worth $3,060,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Amalgamated Bank boosted its stake in Tarsus Pharmaceuticals by 30.1% in the first quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock valued at $65,000 after acquiring an additional 295 shares during the period. Allianz Asset Management GmbH bought a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter worth approximately $227,000. Strs Ohio acquired a new position in Tarsus Pharmaceuticals during the 1st quarter valued at approximately $288,000. Adage Capital Partners GP L.L.C. acquired a new position in Tarsus Pharmaceuticals during the 1st quarter valued at approximately $26,199,000. Finally, Vanguard Group Inc. grew its stake in Tarsus Pharmaceuticals by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company’s stock worth $114,380,000 after buying an additional 111,433 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total value of $332,220.00. Following the transaction, the chief executive officer owned 812,106 shares of the company’s stock, valued at approximately $44,966,309.22. This represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William J. Phd Link sold 27,116 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the sale, the director owned 143,332 shares in the company, valued at $8,169,924. This represents a 15.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 39,116 shares of company stock worth $2,177,832. 8.97% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS opened at $68.25 on Friday. The company has a quick ratio of 5.21, a current ratio of 4.29 and a debt-to-equity ratio of 0.22. The business’s 50-day moving average price is $62.76 and its 200 day moving average price is $51.24. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $76.81. The firm has a market cap of $2.90 billion, a P/E ratio of -33.79 and a beta of 0.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. The company had revenue of $118.70 million for the quarter, compared to analysts’ expectations of $114.22 million. As a group, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TARS has been the subject of several analyst reports. HC Wainwright boosted their price target on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a report on Monday, October 20th. Guggenheim lifted their price objective on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a research report on Wednesday. The Goldman Sachs Group restated a “neutral” rating and issued a $51.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Finally, Wall Street Zen upgraded Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $69.83.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.